San Francisco, CA1 Active Studies

Von Willebrand Disease Clinical Trials in San Francisco, CA

Find 1 actively recruiting von willebrand disease clinical trials in San Francisco, CA. Connect with local research sites and explore new treatment options.

1
Active Trials
1
Sponsors
60
Enrolling

Recruiting Von Willebrand Disease Studies in San Francisco

About Von Willebrand Disease Clinical Trials in San Francisco

Von Willebrand disease is the most common inherited bleeding disorder, caused by deficiency or dysfunction of von Willebrand factor, a protein needed for blood clotting. Most cases are mild with excessive bleeding during surgery or dental work. Treatment includes desmopressin and von Willebrand factor concentrates.

There are currently 1 von willebrand disease clinical trials recruiting participants in San Francisco, CA. These studies are seeking a combined 60 participants. Research is being sponsored by Vega Therapeutics, Inc. Clinical trial participation is free and participants receive study-related medical care at no cost.

Von Willebrand Disease Clinical Trials in San Francisco — FAQ

Are there von willebrand disease clinical trials in San Francisco?

Yes, there are 1 von willebrand disease clinical trials currently recruiting in San Francisco, CA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in San Francisco?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the San Francisco research site will contact you about next steps.

Are clinical trials in San Francisco free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many San Francisco studies also compensate for your time and travel.

What von willebrand disease treatments are being tested?

The 1 active trials in San Francisco are testing new therapies including novel drugs, biologics, and treatment approaches for von willebrand disease.

Data updated July 13, 2026 from ClinicalTrials.gov